Oversubscribed financing led by Jeito Capital, including additional new investment from Vida Ventures, BPI France, and EIFO, with participation from all existing investors

超额认购的融资由Jeito Capital领投，Vida Ventures、BPI France和EIFO新增投资，所有现有投资者亦有参与。

Proceeds to support the advancement of three first- and best-in-class ADC programs through upcoming clinical milestones

通过即将到来的临床里程碑，支持三个一流和同类最佳的ADC项目的发展。

COPENHAGEN, Denmark

哥本哈根，丹麦

,

，

April 14, 2026

2026年4月14日

/PRNewswire/ -- Adcendo, a biotech company focused on the development of first-and best-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need, today announced the successful closing of an oversubscribed $75 million Series C financing round. Proceeds from the fundraise will be used to support Adcendo through multiple upcoming key clinical milestones from the Company's first- and best-in-class ADC pipeline, including the ADCE-T02 (Tissue Factor ADC) Phase I Tiffany-01 Cohort expansion study in multiple high unmet need tumor indications, the ADCE-D01 (uPARAP) ADCElerate1 dose escalation and expansion study in soft tissue sarcoma and other cancers of mesenchymal origin, and the ADCE-B05 (undisclosed target) dose escalation study in squamous cell carcinomas..

/PRNewswire/ -- Adcendo是一家专注于开发一流和最佳抗体药物偶联物（ADC）的生物技术公司，旨在治疗具有高度未满足医疗需求的癌症。该公司今日宣布成功完成了超额认购的7500万美元C轮融资。此次融资所得将用于支持Adcendo完成其一流和最佳ADC管线中的多个即将到来的关键临床里程碑，包括ADCE-T02（组织因子ADC）I期Tiffany-01队列扩展研究，针对多种高需求未满足的肿瘤适应症；ADCE-D01（uPARAP）ADCElerate1剂量递增与扩展研究，针对软组织肉瘤及其他间充质来源的癌症；以及ADCE-B05（未公开靶点）在鳞状细胞癌中的剂量递增研究。

The financing round was led by Jeito Capital, with participation from additional new investors Vida Ventures, BPI France, and EIFO (Export and Investment Fund of Denmark), as well as all existing investors, including TCGX, RA Capital Management, TPG, Orbimed, Venrock, Surveyor, Logos Capital, Novo Holdings, Pontifax Venture Capital, Dawn Biopharma, a platform controlled by KKR, HealthCap, Gilde Healthcare and Ysios Capital..

本轮融资由Jeito Capital领投，新加入的投资者包括Vida Ventures、BPI France和丹麦出口投资基金会（EIFO），以及所有现有投资者，包括TCGX、RA Capital Management、TPG、Orbimed、Venrock、Surveyor、Logos Capital、Novo Holdings、Pontifax Venture Capital、Dawn Biopharma（KKR控制的平台）、HealthCap、Gilde Healthcare和Ysios Capital。

'This successful financing round, led by a distinguished group of life science investors, empowers us to continue advancing our pipeline of breakthrough ADCs for the treatment of underserved cancers,' said Michael Pehl, Chief Executive Officer of Adcendo. 'We are thrilled to see continued momentum of our first and best-in-class ADCs in clinic, and with the backing of this fundraising we will continue to progress ADCE-T02, ADCE-D01 and ADCE-B05 through upcoming data readouts.'.

“这次由一群杰出的生命科学投资者主导的成功融资，使我们能够继续推进我们用于治疗未被充分关注的癌症的突破性ADC药物管线。” Adcendo首席执行官Michael Pehl表示，“我们很高兴看到我们首个和同类最佳的ADC药物在临床中持续取得进展，并且通过此次融资的支持，我们将继续推动ADCE-T02、ADCE-D01和ADCE-B05迎来即将到来的数据读取。”

Ksenija Pavletic, General Partner & Chief Commercial Officer at Jeito Capital, commented: 'Adcendo stands out in the ADC field as having a noteworthy combination of bold innovation and strong clinical development strategy and execution. With a seasoned team of drug developers and biopharma leaders advancing their differentiated pipeline, we are excited to see the Company's progress toward their mission of delivering next-generation cancer therapies to patients who need them most.'.

Jeito Capital的普通合伙人兼首席商务官克塞尼娅·帕夫莱蒂奇评论道：“Adcendo在ADC领域脱颖而出，因其大胆的创新与强大的临床开发战略和执行力相结合而备受瞩目。凭借一支经验丰富的药物开发团队和生物制药领域的领导者推动其差异化的研发管线，我们非常期待看到该公司朝着为最需要的患者提供下一代癌症疗法的使命取得进展。”

As part of the financing, Adcendo will add Ksenija Pavletic (Jeito Capital) and Rajul Jain (Vida Ventures) to its Board of Directors.

作为融资的一部分，Adcendo 将把 Ksenija Pavletic（Jeito Capital）和 Rajul Jain（Vida Ventures）加入其董事会。

About Adcendo ApS:

关于Adcendo ApS：

Adcendo ApS is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with operations in Boston, Massachusetts. The company is developing a pipeline of first- and potential best-in-class antibody-drug conjugates (ADCs) targeting cancers with high unmet medical needs. Led by a team of experienced biopharma executives with a track record of advancing multiple ADCs to approval, Adcendo integrates novel targets, optimized linker-payload combinations, and a rationally designed development strategy to drive next-generation cancer therapies.

Adcendo ApS 是一家临床阶段的生物技术公司，总部位于丹麦哥本哈根，在美国马萨诸塞州波士顿设有业务。该公司正在开发一系列针对具有高度未满足医疗需求的癌症的首创及潜在最佳抗体药物偶联物（ADC）。在一批拥有推动多款ADC获批经验的资深生物制药高管领导下，Adcendo 通过整合新颖靶点、优化的连接子-载荷组合以及合理设计的开发策略，致力于推动下一代癌症治疗药物的发展。

Adcendo is currently advancing three ADCs: 1) ADCE-T02 targeting Tissue Factor, which is overexpressed in a broad range of solid tumors, including head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, colorectal cancer and non-small cell lung cancer; 2) ADCE-D01 targeting uPARAP, which is overexpressed in high unmet need cancers, including soft tissue sarcoma and other cancers of mesenchymal origin; and 3) ADCE-B05, for which the target is undisclosed, is currently being evaluated pre-clinically in squamous cell solid tumors.

Adcendo目前正在推进三种ADC药物：1）针对组织因子（Tissue Factor）的ADCE-T02，该因子在多种实体瘤中过度表达，包括头颈部鳞状细胞癌、胰腺导管腺癌、结直肠癌和非小细胞肺癌；2）针对uPARAP的ADCE-D01，该因子在高度未满足需求的癌症中过度表达，包括软组织肉瘤和其他间充质来源的癌症；3）靶点尚未公开的ADCE-B05，目前正在进行针对鳞状细胞实体瘤的临床前评估。

For further information, please visit .

如需更多信息，请访问 。

https://adcendo.com

https://adcendo.com

or follow us on

或关注我们

LinkedIn

领英

.

。

About Jeito Capital:

关于Jeito Capital：

Jeito Capital is a global leading Private Equity fund with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. With €1.6bn in assets under management, Jeito Capital empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients' access globally, especially in Europe and the United States.

Jeito Capital是一家全球领先的私募股权基金，以患者利益为导向，为突破性的医疗创新提供资金支持并加速其发展和增长。Jeito Capital管理着16亿欧元的资产，通过其专业、综合、多才多艺的团队赋予和支持管理者，并通过大量资本投资确保公司成长，在各自的治疗领域打造市场领导者，加速全球尤其是欧洲和美国患者的获取途径。

Jeito Capital has built a diversified portfolio of clinical Biopharmas with cutting-edge innovations addressing high unmet needs. Jeito Capital is based in Paris with a presence in Europe and the United States..

Jeito Capital打造了一个多元化的临床生物制药组合，拥有满足高度未满足需求的尖端创新。Jeito Capital总部位于巴黎，在欧洲和美国均有业务。

For more information, please visit

更多信息，请访问

www.jeito.life

www.jeito.life

or follow us on

或关注我们

LinkedIn

领英

.

。

SOURCE Adcendo

来源：Adcendo

21

21

%

%

more press release views with

更多新闻稿浏览量与

Request a Demo

请求演示